# The Impact of Diabetes on Patients with Glomerular Disease: CureGN-Diabetes

> **NIH NIH R01** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2022 · $651,102

## Abstract

ABSTRACT
Primary glomerular diseases often occur in patients with prexisting diabetes mellitus, a common and systemic
illness which increases the risk for infection, cardiovascular and progressive chronic kidney disease. The
diagnosis, pathology, treatment, complications and outcomes of primary glomerular diseases may be modified
by the risks associated with diabetes, however, the literature is greatly lacking in this area. Such information is
crucial to optimizing beneficial therapies and minimizing complications and cost in the care of glomerular
disease patients. CureGN-Diabetes is a prospective, longitudinal observational study of patients with one of
the four most common primary glomerular diseases: IgA nephropathy (IgAN), focal segmental
glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN). It is an
ancillary study to the parent CureGN study which is currently in its second cycle of NIH/NIDDK funding and has
enrolled 2400 patients with IgAN, FSGS, MCD and MN, but excluded patients with diabetes prevalent at the
time of glomerular disease diagnosis. The exclusion of diabetes had an unexpected and disproportionate effect
on recruitment among minorities and sites in the southeastern U.S., as these populations suffer among the
highest rates of diabetes. CureGN-Diabetes will fill this gap in the CureGN study and will also leverage control
data from the TRIDENT Study, a longitudinal cohort of patients with biopsy proven diabetic glomerulosclerosis.
Harmonization of data from CureGN, TRIDENT and CureGN-Diabetes, will provide an opportunity to study the
effects of primary glomerular disease alone, diabetic glomerulosclerosis alone and the combined effects of
primary glomerular disease AND diabetes. The aims of CureGN-GN Diabetes include: 1) To recruit and follow
a multiethnic cohort of 300 adult patients with diabetes mellitus and biopsy documented IgAN, FSGS, MN, and
MCD; 2) To assess the impact of diabetes on presenting features (clinical and histopathologic) and long term
outcomes in patients with IgAN, FSGS, MN, and MCD; AND 3) To identify individual and clusters of
morphologic lesions which carry diagnostic and prognostic value. A strength of this study is the significant
overlap between investigators and clinical sites involved in the CureGN and TRIDENT studies, which will
expedite the efficiency and productivity emanating from this work. Furthermore, the CureGN-Diabetes Study
will add to the available biorepositories of CureGN and TRIDENT, enriching the resources for future biomarker
and mechanistic studies of primary glomerular disease versus diabetes-mediated pathways

## Key facts

- **NIH application ID:** 10370293
- **Project number:** 5R01DK126959-02
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** Andrew Stephen Bomback
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $651,102
- **Award type:** 5
- **Project period:** 2021-03-11 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10370293

## Citation

> US National Institutes of Health, RePORTER application 10370293, The Impact of Diabetes on Patients with Glomerular Disease: CureGN-Diabetes (5R01DK126959-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10370293. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*